Aizant Drug Research Solutions Profile
Key Indicators
- Authorised Capital ₹ 26.00 Cr
- Paid Up Capital ₹ 24.69 Cr
- Company Age 19 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 19.46 Cr
- Satisfied Charges ₹ 50.85 Cr
- Revenue Growth 13.98%
- Profit Growth 1.41%
- Ebitda -2.33%
- Net Worth 16.30%
- Total Assets 24.09%
About Aizant Drug Research Solutions
Aizant Drug Research Solutions Private Limited (ADRSPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 22 November 2005 and has a history of 19 years and three months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Innodev Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 26.00 Cr and a paid-up capital of Rs 24.69 Cr.
The company currently has active open charges totaling ₹19.46 Cr. The company has closed loans amounting to ₹50.85 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Aizant Drug Research Solutions Private Limited India is Srinivasa Rani as COMPANY SECRETARY. Varma S, Nookala Narayana, Tirunelveli Devarajan, and One other member serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24239TG2005PTC048133
- Company No.
048133
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Nov 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Aizant Drug Research Solutions Private Limited offer?
Aizant Drug Research Solutions Private Limited offers a wide range of products and services, including Textile, Dyeing & Finishing Chemical, Textile Chemical, Pharma Ingredients & Raw Materials, Anti Infective API, Flavours & Aromatics, Artificial Sweetener, Industrial Chemicals & Supplies, Fragrance Chemicals, Fire Fighting & Prevention Products, Fire Fighting Equipments.
Who are the key members and board of directors at Aizant Drug Research Solutions?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varma S  | Managing Director | 22-Nov-2005 | Current |
| Srinivasa Rani | Company Secretary | 28-Jun-2022 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nookala Narayana  | Director | 04-Dec-2008 | Current |
| Tirunelveli Devarajan | Director | 27-Mar-2017 | Current |
| Rudraraju Sneha | Additional Director | 16-May-2024 | Current |
Financial Performance of Aizant Drug Research Solutions.
Aizant Drug Research Solutions Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.98% increase. The company also saw a slight improvement in profitability, with a 1.41% increase in profit. The company's net worth Soared by an impressive increase of 16.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aizant Drug Research Solutions?
In 2023, Aizant Drug Research Solutions had a promoter holding of 47.85% and a public holding of 52.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Malladi Drugs And Pharmaceuticals LimitedTirunelveli Devarajan is a mutual person
Alniche Lifesciences Private LimitedTirunelveli Devarajan is a mutual person
Ankura Medical & Research Centre Private LimitedTirunelveli Devarajan is a mutual person
Phasorz Technologies Private LimitedTirunelveli Devarajan is a mutual person
Aizen Algo Private LimitedVarma S and Rudraraju Sneha are mutual person
Sandor Life Sciences Private LimitedTirunelveli Devarajan is a mutual person
Charges (Loans)
₹19.46 Cr
₹50.85 Cr
Charges Breakdown by Lending Institutions
- Others : 16.56 Cr
- State Bank Of India : 2.90 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2023 | State Bank Of India | ₹2.90 Cr | Open |
| 18 Sep 2020 | Others | ₹3.81 Cr | Open |
| 23 Feb 2017 | Others | ₹12.75 Cr | Open |
| 12 Oct 2021 | Others | ₹10.45 Cr | Satisfied |
| 23 Aug 2019 | Others | ₹7.50 Cr | Satisfied |
How Many Employees Work at Aizant Drug Research Solutions?
Aizant Drug Research Solutions has a workforce of 746 employees as of Sep 17, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aizant Drug Research Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aizant Drug Research Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
